[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT00001823":3,"trial-entities:NCT00001823":85,"trial-summary:NCT00001823":92},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":8,"brief_summary":14,"detailed_description":15,"conditions":16,"keywords":22,"study_type":27,"primary_purpose":8,"phases":28,"enrollment_info":29,"interventions":32,"primary_outcomes":33,"secondary_outcomes":45,"sex":46,"minimum_age":47,"maximum_age":8,"healthy_volunteers":48,"eligibility_criteria":49,"std_ages":53,"locations":56,"central_contacts":71,"overall_officials":76,"references":80,"see_also_links":81},"NCT00001823","990128","Evaluation for NCI Surgery Branch Clinical Research Protocols","RECRUITING",null,"2026-08-05","2026-09-08","1999-07-11","National Cancer Institute (NCI)","NIH","Background:\n\nThe National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient.\n\nObjective:\n\nThis study will allow patients to under screening and evaluation for participation in NC-SB Protocols.\n\nEligibility:\n\nPatients 18 years or older must meet the minimum eligibility criteria for an NCI-SB treatment protocol.\n\nDesign\n\nPatients will undergo testing and evaluations as required by the appropriate NCI-SB treatment protocol.","Background:\n\nPotential research candidates undergo thorough screening including laboratory tests, scans, x-rays, and review of pathology slides to determine initial eligibility for National Cancer Institute Surgery Branch (NCI-SB) research protocols.\n\nObjectives:\n\nPermit evaluation of patients referred to the NCI-SB in order to identify individuals who will be suitable candidates for NCI-SB clinical research protocols.\n\nTo assess frequency of HLA type, gene specific mutations or expression of neo antigens in malignant tumors across the population of cancer patients undergoing screening for NCI-SB protocols.\n\nCollect results of screening tests for use on subsequent research protocol as baseline (e.g., pretreatment) values.\n\nEligibility:\n\nAge \\>= 18 years.\n\nPatient suspected of having, or with biopsy proven, malignant disease.\n\nPatient is able to understand and willing to sign a written informed consent document.\n\nPatient is being evaluated for treatment on an NCI-SB protocols..\n\nDesign:\n\nPatients enrolled on this protocol will be evaluated by NCI-SB physicians to determine the individual's suitability for participation in a clinical research protocol. An accrual ceiling of 7,000 patients has been set to meet the screening needs of the NCI-SB.",[17,18,19,20,21],"Synovial Cell Cancer","Melanoma","Colorectal Cancer","Lung Cancer","Bladder Cancer",[23,24,25,26],"Cancer","Gene Therapy","Immunotherapy","Clinical Trial","OBSERVATIONAL",[],{"count":30,"type":31},7000,"ESTIMATED",[],[34,38,42],{"measure":35,"description":36,"timeFrame":37},"Number of individuals suitable for NCI Surgery Branch clinical research protocols","Total number of patients who enroll on NCI Surgery Branch clinical research protocols","25 Years",{"measure":39,"description":40,"timeFrame":41},"Frequency of HLA type, gene specific mutations, or expression of neoantigens in malignant tumors","Frequency of HLA type, gene specific mutations, or expression of neoantigens in tissue and blood samples","25 years",{"measure":43,"description":44,"timeFrame":41},"Results of screening tests","Results of screening tests for use on subsequent research protocol as baseline (e.g., pretreatment) values",[],"ALL","18 Years",false,{"inclusion":50,"exclusion":51,"raw_text":52},[],[],"* INCLUSION CRITERIA:\n\nAge \\>= 18 years.\n\nPatient suspected of having, or with biopsy proven, malignant disease.\n\nPatient is able to understand and willing to sign a written informed consent document.\n\nPatient is being evaluated for treatment on an NCI-SB protocols.\n\nEXCLUSION CRITERIA:\n\nWomen of child-bearing potential who are pregnant or plan to become pregnant because of the potentially dangerous effects of some of the screening procedures (e.g., nuclear medicine or other imaging scans) on the fetus.",[54,55],"ADULT","OLDER_ADULT",[57],{"facility":58,"status":7,"city":59,"state":60,"zip":61,"country":62,"contacts":63,"geoPoint":68},"National Institutes of Health Clinical Center","Bethesda","Maryland","20892","United States",[64],{"name":65,"role":66,"phone":67},"For more information at the NIH Clinical Center contact National Cancer Institute Referral Office","CONTACT","888-624-1937",{"lat":69,"lon":70},38.98067,-77.10026,[72],{"name":73,"role":66,"phone":74,"email":75},"NCI SB Immunotherapy Recruitment Center","(866) 820-4505","irc@nih.gov",[77],{"name":78,"affiliation":12,"role":79},"Steven A Rosenberg, M.D.","PRINCIPAL_INVESTIGATOR",[],[82],{"label":83,"url":84},"NIH Clinical Center Detailed Web Page","https:\u002F\u002Fclinicalstudies.info.nih.gov\u002Fcgi\u002Fdetail.cgi?A_1999-C-0128.html",{"nct_id":4,"conditions":86,"biomarkers":91},[87,88,89,18,90,17],"Bladder Carcinoma","Colorectal Carcinoma","Lung Carcinoma","Solid Neoplasm",[],{"nct_id":4,"found":93,"summary":94,"prompt_version":103},true,{"design":95,"status":96,"heading":6,"summary":97,"follow_up":98,"word_count":99,"commitments":100,"compensation":101,"drugs_mentioned":102},"This is an observational study designed to evaluate patients for suitability for other NCI-SB clinical research protocols. It aims to enroll up to 7000 participants.","completed","This observational study is for people with certain cancers, including melanoma, colorectal, lung, and bladder cancer, who are being considered for treatment protocols at the National Cancer Institute Surgery Branch (NCI-SB). The NCI-SB develops experimental therapies that involve using a patient's own white blood cells to fight cancer. This study helps identify suitable candidates for these treatments by performing screening tests like lab work and scans. Researchers will also look at specific genetic information (HLA type, gene mutations, or neoantigens) in tumors to better understand these cancers. The study aims to enroll up to 7000 participants and will follow outcomes for 25 years.","The study will track information like suitability for protocols, genetic markers, and screening test results for 25 years.",103,"You will undergo testing and evaluations as required by the specific NCI-SB treatment protocol you are being considered for.","Not stated in the trial record.",[],"v2"]